Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 75, Issue 6, Pages 1537-1545Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkaa030
Keywords
-
Funding
- Spanish Ministry of Economy and Competitiveness from the European Regional Development Fund (ERDF) [SAF2013-48971-C2-1-R, CSD2010-00065]
- FPU Grant from the Ministry of Education of Spain [FPU14/01537]
Ask authors/readers for more resources
Objectives: We report the in vivo trypanocidal activity of the bacteriocin AS-48 (lacking toxicity), which is produced by Enterococcus faecalis, against the flagellated protozoan Trypanosoma cruzi, the aetiological agent of Chagas' disease. Methods: We determined the in vivo activity of AS-48 against the T. cruzi Arequipa strain in BALB/c mice (in both acute and chronic phases of Chagas' disease). We evaluated the parasitaemia, the reactivation of parasitaemia after immunosuppression and the nested parasites in the chronic phase by PCR in target tissues. Results: AS-48 reduced the parasitaemia profile in acute infection and showed a noteworthy reduction in the parasitic load in chronic infection after immunosuppression according to the results obtained by PCR (double-checking to demonstrate cure). Conclusions: AS-48 is a promising alternative that provides a step forward in the development of a new therapy against Chagas' disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available